Uncovering Hidden Value in an Expensive-Looking ASX Market
A curious paradox confronts investors surveying the Australian sharemarket in 2026. The headline index appears expensive by historical standards, yet a closer examination reveals that the average stock is trading at a meaningful discount. Understanding this divergence is essential for value investors seeking opportunities beyond the index heavyweights.
The Index Illusion
When weighting ASX shares by market capitalisation, the market sits at approximately a 10 per cent premium to Morningstar’s fair value estimates. Investors buying the benchmark are effectively paying about $1.10 for every dollar of fair value. This premium is driven by the largest, most liquid names that have attracted disproportionate flows through ETFs and superannuation funds.
However, the equal-weighted market valuation tells a starkly different story. Morningstar’s data shows a market-cap-weighted price-to-fair-value ratio of 1.23x across their coverage universe, while the equal-weighted ratio is just 0.91x. The equal-weighted and index-weighted valuations have rarely diverged this much over the past decade, suggesting persistent pockets of value at the lower end of the market.
Sector-Level Dislocations
The valuation gap between sectors has created specific areas of opportunity. According to Morningstar’s analysis, real estate and energy screen as the most attractively priced sectors, with roughly 75 per cent of shares rated either 4 or 5 stars. Healthcare and consumer shares also appear undervalued.
Basic materials, conversely, has swung from attractive to one of the most expensive sectors on the back of strong commodity prices. Interestingly, close to 30 per cent of undervalued shares now carry a narrow or wide moat rating—a crucial consideration for investors seeking sustainable competitive advantages alongside attractive valuations.
Quality at a Discount: Case Studies
Among the standout opportunities identified by Morningstar is Endeavour Group (ASX: EDV), which operates the largest network of liquor stores in Australia through the Dan Murphy’s and BWS brands. The company trades at a 35 per cent discount to Morningstar’s fair value estimate of $5.40 per share, with a wide economic moat underpinned by scale cost advantages in liquor retailing.
Sonic Healthcare (ASX: SHL) presents another compelling case. The global pathology and diagnostic imaging provider trades at a 20 per cent discount to Morningstar’s fair value estimate of $27 per share, carrying a narrow moat rating. Healthcare stocks have faced weak sentiment despite trading at what UBS described as an unprecedented price-to-earnings discount.
The Moat Imperative
The presence of competitive moats is critical when assessing value opportunities in an expensive market. A low valuation alone is insufficient; investors must ensure the company can sustain its competitive advantages through the economic cycle. As Morningstar’s analysis emphasises, a balanced approach combining valuation metrics with moat analysis is essential for identifying genuine value rather than value traps.
The current market structure—where large caps appear expensive but the average stock is undervalued—creates a fertile environment for active stock selection. For disciplined value investors willing to look beyond the headline index, the ASX offers a rich seam of opportunities that passive, index-tracking strategies would systematically miss.
